These results have potential clinical application as there is a striking need to discover targeted therapies for cancers that lack driver, activating kinase mutations and because dasatinib, EGFR inhibitors and MEK inhibitors are all approved drugs. The gene discussed is MAP2K7; the disease is cancer.